Neal Akhave

Assistant Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior to starting KRAS G12Ci; C) Survival outcomes according to PD-L1 status (TPS: tumor proportion score); D) survival outcomes in patients with or without prior immune checkpoint inhibitor therapy.

Year:

2025

A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.

Year:

2025

Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.

Year:

2025

A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.

Year:

2025

A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior to starting KRAS G12Ci; C) Survival outcomes according to PD-L1 status (TPS: tumor proportion score); D) survival outcomes in patients with or without prior immune checkpoint inhibitor therapy.

Year:

2024

A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.

Year:

2024

A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.

Year:

2024

A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.

Year:

2024

A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.

Year:

2024

Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.

Year:

2024

Year:

2024

Year:

2024

Collaborators (28)

Mark Awad

Chief, Thoracic Oncology Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Jianjun Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christine Bestvina

Assistant Professor

University of Chicago Medicine

UNITED STATES
View details

Sandip Patel

Associate Professor

Moores Cancer Center, UC San Diego Health

UNITED STATES
View details

Marina Garassino

Prof

Università degli Studi di Torino

ITALY
View details

Jacobi Hines

Assistant Professor

Northwestern Medicine

UNITED STATES
View details

Qi Wang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mizuki Nishino

King’s College London

UNITED STATES
View details

Petros Christopoulos

-

GERMANY
View details

Amy L Cummings

UCLA School of Medicine

UNITED STATES
View details

Giorgio V Scagliotti

Chair

University of Turin

ITALY
View details

james hicks

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Mingjia Li

Assistant Professor

Ohio State University

UNITED STATES
View details

Collin Blakely

Assistant Professor

UCSF Medical Center

UNITED STATES
View details

Matthias Scheffler

University Hospital Bonn

GERMANY
View details

John V. Heymach

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jing Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Heather Wakelee

Professor

Stanford University

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ying Ni

Assistant Professor

Case Western Reserve University

UNITED STATES
View details

Catherine Shu

Columbia University Irving Medical Center

UNITED STATES
View details

Ferdinandos Skoulidis

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Albrecht Stenzinger

-

GERMANY
View details

Marcelo Negrao

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Don L. Gibbons

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Dwight H. Owen

Ohio State University

UNITED STATES
View details